Developer docs
API playgroundTry for free, no card

Search company profiles

Boiron

Full company profile

uuid0004bnj

Namestring
Boiron
Legal namestring
Les Laboratoires BOIRON
Websiteurl
boiron.fr
Company typeenum
Private
Founded yearint
1932
Descriptiontext

Boiron is a French pharmaceutical company founded in 1932 in Lyon that manufactures and distributes homeopathic medicines, dietary supplements, cosmetics, biocides, and storage solutions for consumer health. Its portfolio is anchored by Arnica-based product lines (Arnica, Arnicare, Arnipatch) and extended through brands such as Oscillo, Stodal Plantes, Homeodent, Dapis, Dermoplasmine, Magnésium, and the more recently launched CBD by Boiron (October 2023) and ThroatCalm Spray (October 2024). Manufacturing is built around a proprietary three-step process — controlled dilution, standardized dynamization (150 shakes over 7 seconds), and triple impregnation — executed at facilities in Messimy (HQ), Montévrain, and Lyon under BPF (France) and GMP (USA) certifications with routine ANSM and FDA inspections. Approximately 2,600 employees worldwide support production, with 1,700 based in France.

The company monetizes primarily through unit-priced sales of one-time-purchase products distributed via French pharmacies (where pharmacist-dispensed pricing applies) and an e-commerce boutique selling supplements, cosmetics, and CBD wellness items. Internationally, Boiron operates 21 wholly-owned subsidiaries and roughly 20 local distributors reaching nearly 50 countries, generating approximately 60% of group revenue outside France. Revenue for 2025 was reported at EUR 501 million. Beyond consumer products, Boiron monetizes clinical credibility through institutional partnerships — including INSERM, CNRS Lyon, University of Basel, the Homeopathy Research Institute, Institut Rafaël (integrative oncology since 2019), and France's medical cannabis pilot — and uses an enterprise field-sales motion targeting physicians, pharmacists, midwives, gynecologists, and oncologists via the boiron-pro.fr portal.

Ownership and governance are family-controlled: Anabelle Flory-Boiron chairs the Board, Pascal Houdayer serves as Director General since 2024, and Thierry Boiron acts as Deputy CEO. In 2024 EW Healthcare Partners became a minority shareholder in Boiron Développement, introducing the first external institutional capital. A EUR 3.2 million investment in Panaxia Pharmaceutical Industries (Malta) in 2026, with a call option to take a majority stake by 2029, signals expansion into regulated medical cannabis alongside the existing homeopathy core.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersRontalon, France
HQ citystring
Rontalon
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices9 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
homeopathic medicines, pharmaceutical manufacturing, dietary supplements, natural health products, integrative medicine
Industry3 codes
1Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
CodeHLAIAAAEPrimaryYes
2Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges)
CodeCRADAMADPrimaryNo
3Compounding Pharmacies (Veterinary)
CodeHLAMAIADPrimaryNo
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing32541
  • Drugs and Druggists' Sundries Merchant Wholesalers42421
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Homeopathic Pharmaceuticals
Social media profiles2 records
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model6 records
1Homeopathic medicines
TypeOne Time License
Description

Sale of homeopathic medications for human and veterinary use, sold primarily through pharmacy networks in France and internationally through subsidiaries

boiron.fr
2Dietary supplements
TypeOne Time License
Description

Sale of food supplements (compléments alimentaires) through the online boutique and pharmacies

boiron.fr
3Cosmetics
TypeOne Time License
Description

Sale of cosmetics including Arnipatch patches, CBD massage oils, and diaper change cream through pharmacy and e-commerce channels

boiron.fr
4CBD wellness products
TypeOne Time License
Description

CBD-based wellness products under the CBD by Boiron brand, launched in October 2023

boiron.fr
5Biocides
TypeOne Time License
Description

Mosquito repellent and other biocidal products

boiron.fr
6Storage solutions
TypeOne Time License
Description

Organizational and storage products for health products

boiron.fr
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Personnel, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure
Pricing details2 tiers
1Products sold through pharmacy network requiring professional consultation
ModelOtherBilling cadencePay-as-you-go
Notes

Homeopathic medicines are dispensed through pharmacies in France with pricing determined by pharmacy regulations

boiron.fr
2E-commerce boutique for supplements, cosmetics, and wellness products
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Online store offers dietary supplements, cosmetics, CBD products, and organizational solutions for direct consumer purchase

boiron.fr
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 10 records shown
1Arnica
Description

Homeopathic pain relief brand featuring Arnica-based products for muscle pain, stiffness, and recovery

boiron.fr
+9 more records
Core offering1 text field

Boiron manufactures and distributes a portfolio of homeopathic medicines (custom homeopathy, conventional medicines, veterinary homeopathy), dietary supplements, cosmetics, CBD wellness products, biocides, and storage solutions. Products are sold primarily through pharmacy networks in France and through 21 international subsidiaries plus local distributors across nearly 50 countries worldwide. Flagship lines include Arnica/Arnicare for pain and recovery, Oscillo and Stodal Plantes for respiratory wellness, Homeodent for oral care, and CBD by Boiron wellness products.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 200 million people worldwide use homeopathic medicines
+4 more records
Product overview1 text field

Boiron offers a diversified portfolio of homeopathic medicines, dietary supplements, cosmetics, and wellness products distributed through pharmacies. The core offering centers on homeopathic remedies using Arnica as a flagship ingredient across multiple product lines (Arnica, Arnicare, Arnipatch). The portfolio expands into CBD-based wellness products (CBD by Boiron), oral care (Homeodent), respiratory support (Stodal Plantes, Oscillo), and topical solutions (Dapis, Dermoplasmine). Products are categorized into three main families: custom homeopathy, conventional medicines, and veterinary homeopathic medicines, complemented by dietary supplements, cosmetics, CBD wellness products, and biocides sold through pharmacies and the e-commerce boutique.

Product and service11 records
1Arnica product line
CategoryHomeopathic medicine - traumatology
2CBD by Boiron
CategoryCBD wellness products
3Oscillo' food supplement
CategoryDietary supplement - immune/wellness
4Arnipatch cosmetic patch
CategoryCosmetic product
5Dapis homeopathic line
CategoryHomeopathic medicine
6Dermoplasmine skincare line
CategoryHomeopathic skincare
7Homeodent oral care line
CategoryHomeopathic oral care
8Magnesium supplement line
CategoryDietary supplement - mineral
9Stodal Plantes cough remedy
CategoryHomeopathic medicine - respiratory
10ThroatCalm Spray
CategoryHomeopathic medicine - ENT
11Arnicare pain relief line
CategoryHomeopathic medicine - sports/traumatology
Scale indicator14 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
1Former MLS star Sébastien Le Toux
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2026-06-01
Description

Arnicare by Boiron partnership with former MLS star Sébastien Le Toux to promote Arnica-based pain relief products during FIFA World Cup 2026, hosting media and influencers at MetLife Stadium during the France vs. Senegal match.

prnewswire.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-01
Description

Boiron invested EUR 3.2 million in Panaxia Malta as part of strategic partnership. Boiron received a call option to acquire a majority stake by 2029. Both companies have been active in France's medical cannabis pilot program since 2019, which has enabled 3,000 patients to access regulated treatments.

3Podcast 'Allez j'ose!'
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2024-01-01
Description

Boiron partnered with the 'Allez j'ose!' podcast hosted by Elsa Wolinski, which addresses menopause awareness without taboos, featuring women and health experts.

boiron.fr
4Entreprise des Possibles
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2023-01-01
Description

Boiron joined 'Entreprise des Possibles' in 2023, a solidarity initiative among Lyon companies, becoming the 150th member company.

boiron.fr
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2020-01-01
Description

Long-standing partnership supporting the 'Courir POUR ELLES' solidarity race dedicated to fighting women's cancers. Boiron sponsors the Bouger POUR ELLES initiative.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-01-01
Description

Boiron is a partner of Institut Rafaël, an integrative medicine center in Levallois-Perret providing comprehensive cancer care. Boiron co-organized the first Integrative Oncology Days in 2019, bringing together practitioners from around the world.

7France medical cannabis pilot program
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-01-01
Description

Both Boiron and Panaxia have been active in France's medical cannabis pilot program since 2019, enabling 3,000 patients to access regulated treatments.

carlsquare.com
Strategic tierCoreTypeTechnology or Integration
Description

Boiron collaborates with INSERM on fundamental and clinical research in homeopathy, particularly in areas of respiratory infections, nervous system, oncology support, and traumatology.

Strategic tierCoreTypeTechnology or Integration
Description

Collaborative research partnership with CNRS Lyon for fundamental research on homeopathic mechanisms and natural substance behaviors.

Strategic tierCoreTypeTechnology or Integration
Description

International academic research partnership for homeopathy research and scientific collaboration.

Strategic tierCoreTypeTechnology or Integration
Description

Academic research collaboration for fundamental and clinical studies in homeopathy.

Strategic tierCoreTypeTechnology or Integration
Description

UK-based institute plays an essential role in supporting scientific research and disseminating findings to the public and healthcare professionals. Boiron supports HRI's mission for global homeopathy research.

Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Heel is a German-based pharmaceutical company specializing in homeopathic and natural medicines, producing combination homeopathic preparations distributed globally. It directly competes with Boiron in the European homeopathy market with similar product formats, pharmacy distribution, and clinical positioning across musculoskeletal, respiratory, and pediatric indications.

2Deutsche Homöopathie-Union (DHU) / Schwabe Group
TypeDirect peer
Description

Schwabe Group's DHU subsidiary is one of the largest homeopathic medicine manufacturers in Germany, with a portfolio spanning single remedies, complex formulations, and Schuessler salts. It is a direct competitor to Boiron in pharmacy-channel homeopathic products, with comparable regulatory expertise and international footprint across Europe and emerging markets.

3Nelsons (Nelsonbach)
TypeDirect peer
Description

Nelsons is a UK-based homeopathic manufacturer producing Rescue Remedy, Bach Flower Remedies, and homeopathic medicines. It competes directly with Boiron in UK and international consumer homeopathy markets with similar pharmacy and natural health store distribution, sharing end-user segments in stress, sleep, and general wellness.

TypeDirect peer
Description

Hyland's is a US-based homeopathic medicine manufacturer with a broad OTC portfolio spanning cold/cough, sleep, pain relief, and teething products. It is Boiron's most direct US competitor in pharmacy-channel homeopathic products, particularly in the pediatric segment (teething, cold) where Boiron also targets parents seeking gentle treatments.

TypeDirect peer
Description

Similasan is a Swiss-headquartered homeopathic manufacturer specializing in OTC eye, ear, and nasal products distributed in the US and Europe. It is a direct peer in pharmacy-channel homeopathic OTC products, overlapping with Boiron in consumer health categories and natural remedies positioning.

TypeBroad incumbent
Description

Pierre Fabre is a major French pharmaceutical and dermo-cosmetic company with a broad portfolio spanning prescription drugs, OTC products, and natural health. While not homeopathy-focused, it competes with Boiron in French pharmacy channels across dermatology, pediatrics, and consumer health categories where both brands occupy shelf space.

TypeBroad incumbent
Description

Sanofi operates a broad consumer healthcare portfolio including OTC medications, dietary supplements, and pharmacy-distributed brands across cough/cold, pain, and wellness categories. It competes with Boiron in pharmacy channels globally and represents the larger-scale incumbents that can leverage broader R&D, regulatory, and distribution resources.

TypeBroad incumbent
Description

Bayer's Consumer Health division includes OTC brands across pain, cold/flu, dermatology, and nutrition sold through pharmacy channels worldwide. It is a broad incumbent that competes with Boiron across multiple therapeutic categories in pharmacy retail, particularly in cough/cold (Stodal/Oscillo overlap with Bayer products) and topical pain relief.

TypeEmerging player
Description

Weleda is a Swiss-based natural cosmetics and anthroposophic medicine manufacturer with a portfolio overlapping Boiron's in natural skincare, baby care, and plant-based wellness products. While not strictly homeopathic, it competes for the same natural-medicine consumer and pharmacy distribution channels across Europe.

TypeEmerging player
Description

A.Vogel (Bioforce) is a Swiss manufacturer of herbal and natural medicines focused on plant-based OTC products distributed through pharmacies and health stores. It is an emerging player in the natural pharmacy channel that competes with Boiron in stress, sleep, immunity, and women's health categories where consumer overlap is meaningful.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment9 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile6 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Boiron

Homeopathic Pharmaceuticalsboiron.fr

What Boiron does

Boiron is a French pharmaceutical company founded in 1932 in Lyon that manufactures and distributes homeopathic medicines, dietary supplements, cosmetics, biocides, and storage solutions for consumer health. Its portfolio is anchored by Arnica-based product lines (Arnica, Arnicare, Arnipatch) and extended through brands such as Oscillo, Stodal Plantes, Homeodent, Dapis, Dermoplasmine, Magnésium, and the more recently launched CBD by Boiron (October 2023) and ThroatCalm Spray (October 2024). Manufacturing is built around a proprietary three-step process — controlled dilution, standardized dynamization (150 shakes over 7 seconds), and triple impregnation — executed at facilities in Messimy (HQ), Montévrain, and Lyon under BPF (France) and GMP (USA) certifications with routine ANSM and FDA inspections. Approximately 2,600 employees worldwide support production, with 1,700 based in France.

The company monetizes primarily through unit-priced sales of one-time-purchase products distributed via French pharmacies (where pharmacist-dispensed pricing applies) and an e-commerce boutique selling supplements, cosmetics, and CBD wellness items. Internationally, Boiron operates 21 wholly-owned subsidiaries and roughly 20 local distributors reaching nearly 50 countries, generating approximately 60% of group revenue outside France. Revenue for 2025 was reported at EUR 501 million. Beyond consumer products, Boiron monetizes clinical credibility through institutional partnerships — including INSERM, CNRS Lyon, University of Basel, the Homeopathy Research Institute, Institut Rafaël (integrative oncology since 2019), and France's medical cannabis pilot — and uses an enterprise field-sales motion targeting physicians, pharmacists, midwives, gynecologists, and oncologists via the boiron-pro.fr portal.

Ownership and governance are family-controlled: Anabelle Flory-Boiron chairs the Board, Pascal Houdayer serves as Director General since 2024, and Thierry Boiron acts as Deputy CEO. In 2024 EW Healthcare Partners became a minority shareholder in Boiron Développement, introducing the first external institutional capital. A EUR 3.2 million investment in Panaxia Pharmaceutical Industries (Malta) in 2026, with a call option to take a majority stake by 2029, signals expansion into regulated medical cannabis alongside the existing homeopathy core.

Boiron firmographics

Firmographics
Name
Boiron
Legal name
Les Laboratoires BOIRON
Website
https://boiron.fr
Company type
Private
Founded year
1932
Operating status
Operating
Headcount range
1,001–5,000 employees
Ownership category
akta.pro rank

Boiron industry classification

Industry
Product category
Homeopathic Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Drugs and Druggists' Sundries Merchant Wholesalers (42421)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro primary industry
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)
akta.pro secondary industries
Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges) (CRADAMAD), Compounding Pharmacies (Veterinary) (HLAMAIAD)

Keywords

  • Homeopathic medicines
  • Pharmaceutical manufacturing
  • Dietary supplements
  • Natural health products
  • Integrative medicine

Where Boiron is headquartered

Location

Headquarters

HQ city
Rontalon
HQ country
France
HQ region
Europe

Offices9 records

Markets served

Boiron business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Operations, Personnel, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. Homeopathic medicines: Sale of homeopathic medications for human and veterinary use, sold primarily through pharmacy networks in France and internationally through subsidiaries
  2. Dietary supplements: Sale of food supplements (compléments alimentaires) through the online boutique and pharmacies
  3. Cosmetics: Sale of cosmetics including Arnipatch patches, CBD massage oils, and diaper change cream through pharmacy and e-commerce channels
  4. CBD wellness products: CBD-based wellness products under the CBD by Boiron brand, launched in October 2023
  5. Biocides: Mosquito repellent and other biocidal products
  6. Storage solutions: Organizational and storage products for health products

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goProducts sold through pharmacy network requiring professional consultation
Unit PricingPay-as-you-goE-commerce boutique for supplements, cosmetics, and wellness products

Go-to-market motion4 records

Distribution channels6 records

Marketing channels8 records

Boiron product offering

Product offering

Core offering

Boiron manufactures and distributes a portfolio of homeopathic medicines (custom homeopathy, conventional medicines, veterinary homeopathy), dietary supplements, cosmetics, CBD wellness products, biocides, and storage solutions. Products are sold primarily through pharmacy networks in France and through 21 international subsidiaries plus local distributors across nearly 50 countries worldwide. Flagship lines include Arnica/Arnicare for pain and recovery, Oscillo and Stodal Plantes for respiratory wellness, Homeodent for oral care, and CBD by Boiron wellness products.

Product overview

Boiron offers a diversified portfolio of homeopathic medicines, dietary supplements, cosmetics, and wellness products distributed through pharmacies. The core offering centers on homeopathic remedies using Arnica as a flagship ingredient across multiple product lines (Arnica, Arnicare, Arnipatch). The portfolio expands into CBD-based wellness products (CBD by Boiron), oral care (Homeodent), respiratory support (Stodal Plantes, Oscillo), and topical solutions (Dapis, Dermoplasmine). Products are categorized into three main families: custom homeopathy, conventional medicines, and veterinary homeopathic medicines, complemented by dietary supplements, cosmetics, CBD wellness products, and biocides sold through pharmacies and the e-commerce boutique.

Differentiator

Problem solved

Functional benefit

Brands

  • Arnica: Homeopathic pain relief brand featuring Arnica-based products for muscle pain, stiffness, and recovery
  • CBD by Boiron
  • Dapis
  • Dermoplasmine
  • Homeodent
  • Oscillo
  • Stodal Plantes
  • Arnicare
  • ThroatCalm
  • Arnipatch

Products and services

  • Arnica product line
  • CBD by Boiron
  • Oscillo' food supplement
  • Arnipatch cosmetic patch
  • Dapis homeopathic line
  • Dermoplasmine skincare line
  • Homeodent oral care line
  • Magnesium supplement line
  • Stodal Plantes cough remedy
  • ThroatCalm Spray
  • Arnicare pain relief line

Quantifiable outcome

  • 200 million people worldwide use homeopathic medicines
  • +4 more outcomes

Companies that use Boiron

Customer profile

Named customers3 records

Segments9 records

Ideal customer profiles6 records

Boiron technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Boiron partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered minor and core.

  • Former MLS star Sébastien Le TouxminorGTM or Marketing Partner · 1 June 2026Arnicare by Boiron partnership with former MLS star Sébastien Le Toux to promote Arnica-based pain relief products during FIFA World Cup 2026, hosting media and influencers at MetLife Stadium during the France vs. Senegal match.
  • Panaxia Pharmaceutical Industries (Malta)coreStrategic or Co-development Partner · 1 April 2026Boiron invested EUR 3.2 million in Panaxia Malta as part of strategic partnership. Boiron received a call option to acquire a majority stake by 2029. Both companies have been active in France's medical cannabis pilot program since 2019, which has enabled 3,000 patients to access regulated treatments.
  • Podcast 'Allez j'ose!'minorGTM or Marketing Partner · 1 January 2024Boiron partnered with the 'Allez j'ose!' podcast hosted by Elsa Wolinski, which addresses menopause awareness without taboos, featuring women and health experts.
  • Entreprise des PossiblesminorGTM or Marketing Partner · 1 January 2023Boiron joined 'Entreprise des Possibles' in 2023, a solidarity initiative among Lyon companies, becoming the 150th member company.
  • Courir POUR ELLESminorGTM or Marketing Partner · 1 January 2020Long-standing partnership supporting the 'Courir POUR ELLES' solidarity race dedicated to fighting women's cancers. Boiron sponsors the Bouger POUR ELLES initiative.
  • Institut RafaëlcoreStrategic or Co-development Partner · 1 January 2019Boiron is a partner of Institut Rafaël, an integrative medicine center in Levallois-Perret providing comprehensive cancer care. Boiron co-organized the first Integrative Oncology Days in 2019, bringing together practitioners from around the world.
  • France medical cannabis pilot programcoreStrategic or Co-development Partner · 1 January 2019Both Boiron and Panaxia have been active in France's medical cannabis pilot program since 2019, enabling 3,000 patients to access regulated treatments.
  • INSERM (Institut national de la santé et de la recherche médicale)coreTechnology or IntegrationBoiron collaborates with INSERM on fundamental and clinical research in homeopathy, particularly in areas of respiratory infections, nervous system, oncology support, and traumatology.
  • CNRS de Lyon (Centre National de la Recherche Scientifique)coreTechnology or IntegrationCollaborative research partnership with CNRS Lyon for fundamental research on homeopathic mechanisms and natural substance behaviors.
  • University of BaselcoreTechnology or IntegrationInternational academic research partnership for homeopathy research and scientific collaboration.
  • University of Champagne-ArdennecoreTechnology or IntegrationAcademic research collaboration for fundamental and clinical studies in homeopathy.
  • Homeopathy Research Institute (HRI)coreTechnology or IntegrationUK-based institute plays an essential role in supporting scientific research and disseminating findings to the public and healthcare professionals. Boiron supports HRI's mission for global homeopathy research.

Scale indicators14 records

Recent moves10 records

Expansion highlights6 records

Boiron competitors and assessment

Company assessment

Direct peers

  • Heel Group: Heel is a German-based pharmaceutical company specializing in homeopathic and natural medicines, producing combination homeopathic preparations distributed globally. It directly competes with Boiron in the European homeopathy market with similar product formats, pharmacy distribution, and clinical positioning across musculoskeletal, respiratory, and pediatric indications.
  • Deutsche Homöopathie-Union (DHU) / Schwabe Group: Schwabe Group's DHU subsidiary is one of the largest homeopathic medicine manufacturers in Germany, with a portfolio spanning single remedies, complex formulations, and Schuessler salts. It is a direct competitor to Boiron in pharmacy-channel homeopathic products, with comparable regulatory expertise and international footprint across Europe and emerging markets.
  • Nelsons (Nelsonbach): Nelsons is a UK-based homeopathic manufacturer producing Rescue Remedy, Bach Flower Remedies, and homeopathic medicines. It competes directly with Boiron in UK and international consumer homeopathy markets with similar pharmacy and natural health store distribution, sharing end-user segments in stress, sleep, and general wellness.
  • Hyland's: Hyland's is a US-based homeopathic medicine manufacturer with a broad OTC portfolio spanning cold/cough, sleep, pain relief, and teething products. It is Boiron's most direct US competitor in pharmacy-channel homeopathic products, particularly in the pediatric segment (teething, cold) where Boiron also targets parents seeking gentle treatments.
  • Similasan: Similasan is a Swiss-headquartered homeopathic manufacturer specializing in OTC eye, ear, and nasal products distributed in the US and Europe. It is a direct peer in pharmacy-channel homeopathic OTC products, overlapping with Boiron in consumer health categories and natural remedies positioning.

Broad incumbents

  • Pierre Fabre: Pierre Fabre is a major French pharmaceutical and dermo-cosmetic company with a broad portfolio spanning prescription drugs, OTC products, and natural health. While not homeopathy-focused, it competes with Boiron in French pharmacy channels across dermatology, pediatrics, and consumer health categories where both brands occupy shelf space.
  • Sanofi Consumer Healthcare: Sanofi operates a broad consumer healthcare portfolio including OTC medications, dietary supplements, and pharmacy-distributed brands across cough/cold, pain, and wellness categories. It competes with Boiron in pharmacy channels globally and represents the larger-scale incumbents that can leverage broader R&D, regulatory, and distribution resources.
  • Bayer Consumer Health: Bayer's Consumer Health division includes OTC brands across pain, cold/flu, dermatology, and nutrition sold through pharmacy channels worldwide. It is a broad incumbent that competes with Boiron across multiple therapeutic categories in pharmacy retail, particularly in cough/cold (Stodal/Oscillo overlap with Bayer products) and topical pain relief.

Emerging players

  • Weleda: Weleda is a Swiss-based natural cosmetics and anthroposophic medicine manufacturer with a portfolio overlapping Boiron's in natural skincare, baby care, and plant-based wellness products. While not strictly homeopathic, it competes for the same natural-medicine consumer and pharmacy distribution channels across Europe.
  • A.Vogel / Bioforce: A.Vogel (Bioforce) is a Swiss manufacturer of herbal and natural medicines focused on plant-based OTC products distributed through pharmacies and health stores. It is an emerging player in the natural pharmacy channel that competes with Boiron in stress, sleep, immunity, and women's health categories where consumer overlap is meaningful.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Boiron social profiles

Digital presence

Boiron compliance and trust

Trust signal

Compliance2 records

Boiron financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Boiron leadership team

Management profile

Number of profiles

Profiles10 records

Boiron subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Boiron funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Boiron M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Boiron

What does Boiron do?

Boiron manufactures and distributes a portfolio of homeopathic medicines (custom homeopathy, conventional medicines, veterinary homeopathy), dietary supplements, cosmetics, CBD wellness products, biocides, and storage solutions. Products are sold primarily through pharmacy networks in France and through 21 international subsidiaries plus local distributors across nearly 50 countries worldwide. Flagship lines include Arnica/Arnicare for pain and recovery, Oscillo and Stodal Plantes for respiratory wellness, Homeodent for oral care, and CBD by Boiron wellness products.

Is Boiron a public or private company?

Boiron is a private company. It is classified as family owned and is currently operating.

When was Boiron founded?

Boiron was founded in 1932. It employs 1,001 to 5,000 people.

Where is Boiron based?

Boiron is headquartered in Rontalon, France, in the Europe region.

How does Boiron make money?

Six revenue lines are on record. Homeopathic medicines are the primary driver. The others are dietary supplements, cosmetics, CBD wellness products, biocides and storage solutions.

Who are Boiron's main competitors?

Direct peers on record are Heel Group, Deutsche Homöopathie-Union (DHU) / Schwabe Group, Nelsons (Nelsonbach), Hyland's and Similasan. Broad incumbents are Pierre Fabre, Sanofi Consumer Healthcare and Bayer Consumer Health. Emerging players are Weleda and A.Vogel / Bioforce.

Does Boiron have an API?

No public API is recorded for Boiron.

What industry is Boiron in?

Boiron's product category is Homeopathic Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity), with a secondary code of CRADAMAD, Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business PageBOIRON : Déclaration du nombre d'actions et droits de vote au 31 août 2026BOIRON declared its capital and voting rights as of 31 August 2026, with 17,545,408 total shares and 18,403,615 gross voting rights. Net voting rights, after deducting private rights, total 18,220,482.FinancialContent Business PageBOIRON : Déclaration des droits de vote au 31 juillet 2026Boiron published its voting rights declaration for July 31, 2026, disclosing a total of 17,545,408 shares and a net voting right count of 17,983,145. This regulatory filing complies with Articles L. 233-8 II of the Commercial Code and 223-16 of the AMF General Regulation.Drug Store NewsIs digestive health still a probiotics category?The digestive health supplement market is evolving beyond probiotics as consumers increasingly seek specific symptom relief rather than general microbiome modulation. Companies such as Boiron, Culturelle, Nordic Naturals, and NXT USA are launching diverse products targeting issues like bloating, motility, and constipation with varying scientific backing. This shift challenges the traditional dominance of probiotic ingredients in the category.FinancialContent Business PageBOIRON : Déclaration des droits de vote au 30 juin 2026Boiron published its share capital composition and total voting rights as of June 30, 2026, in compliance with French regulatory requirements. The company has 17,545,408 shares outstanding with 17,813,352 gross voting rights and 17,630,219 net voting rights after excluding self-held shares. This is a routine regulatory disclosure under Articles L. 233-8 II of the French commercial code and AMF General Regulation Article 223-16.PR NewswireARNICARE® BY BOIRON PARTNERS WITH FORMER MLS STAR SÉBASTIEN LE TOUX TO SPOTLIGHT PERFORMANCE RECOVERYArnicare by Boiron has partnered with former MLS star Sébastien Le Toux to promote its Arnica-based pain relief products during the FIFA World Cup 2026, hosting media and influencers at MetLife Stadium during the France vs. Senegal match. Le Toux, who grew up in France using Arnica, will appear alongside Boiron Global CEO Pascal Houdayer and Boiron USA President and CEO Janick Boudazin to discuss recovery culture in professional soccer and integrative wellness. The partnership targets athletes, trainers, and active consumers seeking homeopathic solutions for muscle pain, stiffness, and recovery support.Carlsquare Corporate FinanceCarlsquare advised Panaxia Malta on its strategic partnership with BoironCarlsquare acted as exclusive financial advisor to Panaxia Pharmaceutical Industries on entering a strategic partnership with Boiron, an independent French pharmaceutical laboratory specializing in homeopathic medicines. Boiron invested EUR 3.2 million in Panaxia and received a call option to acquire a majority stake by 2029. Both companies have been active in France's medical cannabis pilot program since 2019, which has enabled 3,000 patients to access regulated treatments.NewsfileBoiron's Camilia Tummy Receives Top Honors from Baby Innovation AwardsBoiron's Camilia Tummy has been awarded "Baby Accessory Product of the Year" at the 2025 Baby Innovation Awards. The recognition highlights the product's utility in providing gentle, convenient relief for infant gas and colic discomfort.YahooBoiron's Camilia Tummy Receives Top Honors from Baby Innovation AwardsBoiron's Camilia Tummy won Baby Accessory Product of the Year at the 2025 Baby Innovation Awards. The liquid dose medicine, made from chamomile, offers gas and colic relief for babies one month and up. It is available over the counter for $13.99 per box of 30 doses.YahooEW Healthcare Partners Acquires Stake in Boiron Group, a Leader in Natural MedicineEW Healthcare Partners acquired a 25% minority stake in Boiron Developpement, the entity launching a tender offer for the Boiron Group, at an enterprise value of approximately €875 million. This transaction involves the Boiron family transferring its controlling interest to Boiron Developpement, solidifying EW's partnership with the company's founders. The deal aims to accelerate Boiron's growth, particularly in expanding its product offerings and U.S. market presence.ActusnewsBOIRONBOIRON family holding companies and EW HEALTHCARE PARTNERS signed an agreement to transfer their majority shareholding in BOIRON to the newly formed entity BOIRON DÉVELOPPEMENT. This transaction precedes a simplified public tender offer valued at €39.64 per share, which represents a significant premium over recent market prices. The deal is subject to regulatory approval from the French Financial Markets Authority (AMF) and shareholder votes.